Articles from Lunaphore

Lunaphore Technologies SA, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced it has reached an agreement to be acquired by Bio-Techne Corporation (NASDAQTECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. The acquisition is anticipated to close in Q3.

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership to enable the use of CST® antibodies on the Lunaphore COMET™ platform, a scalable hyperplex imaging solution for fully automated spatial biology.

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and abcam (NASDAQABCM), a global life science company working together with researchers to advance science and enable faster breakthroughs, today announced an agreement to co-market abcam primary antibodies specifically validated for use on Lunaphore’s COMET™ platform.

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced the launch of a full expansion of its product offering to provide a universal, end-to-end spatial biology solution, answering the needs of the scientific community from early discovery to late-stage translational and clinical research. This milestone marks the launch of the enhanced version of the company’s revolutionary COMET™ platform and its comprehensive product suite, which includes a wide range of tools and applications across all research and drug development stages.

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, announced today that it has completed CHF 40M in Series D1 funding. The round was led by Ernst-Göhner Stiftung Beteiligungen (EGSB) and existing investors PHC Holdings Corporation, Swiss Entrepreneurs Fund, OCCIDENT, and Redalpine participated. The funding includes a EUR 10M venture debt facility provided by Norgine Ventures.

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Sirona Dx, a leader in multi-omics, single-cell analytical services, today announced a strategic collaboration in which Sirona Dx will become the first US-based Contract Research Organization (CRO) to offer Lunaphore’s flagship COMET™ spatial biology platform as a service. COMET™ will complement Sirona Dx’s portfolio of research service offerings to meet the needs of researchers and biopharma teams across various disciplines.

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Visiopharm, a company developing A.I.-driven precision pathology software, today announced a new partnership that will unite staining and imaging with A.I. analysis capabilities. Under the partnership, the companies will co-market a complete end-to-end solution that offers hyperplex immunofluorescence staining, image acquisition, and subsequent analysis with deep learning.

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced it has entered a collaboration with the Pathology Department at Massachusetts General Hospital to develop an in vitro diagnostic (IVD) that evaluates sensitivity of solid tumors to poly-ADP ribose polymerase (PARP) inhibitors, with an initial focus on ovarian, breast and prostate cancers. The project will be led by Markus D. Herrmann, M.D., Ph.D., Director of Computational Pathology at Massachusetts General Hospital, who is also Assistant Professor of Pathology at Harvard Medical School. Lunaphore and Dr. Herrmann will collaborate to develop a multiplexed immunofluorescence assay that can measure the expression of multiple proteins using the COMET platform currently installed at Massachusetts General Hospital.

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced that Alice T. Feng will join the Lunaphore leadership team as Chief Financial Officer, effective January 31, 2022. Ms. Feng brings over two decades of finance and corporate development leadership experience as well as investment banking expertise, participating in over 30 merger and acquisition and financing transactions with aggregate transaction value of $45 billion.

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced the events and activities planned around the inaugural Lunaphore Spatial Biology Week™, taking place virtually December 6-10, 2021. The five-day online meeting will highlight how new technology solutions are lowering the barriers for adoption of spatial biology technologies in a wide range of research laboratories in hospitals, academia, core facilities and the biopharmaceutical industry. Registration is free and open to researchers from Europe and North America.

Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, announces the appointment of Dr. Carlo Bifulco, an expert in Translational Molecular Pathology and Pathology Informatics, to its Scientific Advisory Board (SAB) to provide strategic advisory support to the company’s scientific activities and product portfolio development.